论文部分内容阅读
探索新的、疗效高而毒性小的化疗方案是急性髓性白血病(AML)的常规化疗追求的目标。我院自1993年～1996年用AA方案(阿糖胞苷200mg/d×7天;阿克拉霉素20～40mg/d×7天)对20例AML患者进行化疗,现小结如下。 1 病例和方法 1.1 病例:20例AML患者均为住院病人,符合FAB诊断分型标准。其中M_12例、M_211例,M_32例、M_42例、M_52例,慢性粒细胞性白血病急粒变1例。初治患者16例,其中男性6例,女性10例;年龄21～66岁,平均年龄40岁。复发4例,其中男性2例,女性2例,年龄39～41岁,平均40岁。
Exploring new chemotherapy regimens with high efficacy and low toxicity is the goal of conventional chemotherapy for acute myeloid leukemia (AML). In our hospital from 1993 to 1996, 20 patients with AML were treated with AA regimen (cytarabine 200 mg/d×7 days; aclacinomycin 20 to 40 mg/d×7 days). The summary is as follows. 1 Cases and Methods 1.1 Cases: 20 patients with AML were hospitalized and met the FAB diagnostic criteria. M_12 cases, M_211 cases, M_32 cases, M_42 cases, M_52 cases, 1 case of chronic myeloid leukemia. There were 16 newly diagnosed patients, including 6 males and 10 females; the age ranged from 21 to 66 years and the average age was 40 years. There were 4 cases of recurrence, including 2 males and 2 females, aged 39 to 41 years, with an average of 40 years old.